Clinical Trials
13 trialsNCT00739453 2024-11-20
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
Astellas Pharma Inc
Phase 1 Completed
NCT02737228 2019-06-17
Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
CrystalGenomics, Inc.
Phase 1/2 Unknown
NCT01782690 2018-07-23
An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Hoffmann-La Roche
Completed
NCT00033241 2018-01-10
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
Astellas Pharma Inc
Phase 1 Completed
NCT00040183 2018-01-10
OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
Astellas Pharma Inc
Phase 3 Completed
NCT02694536 2017-03-24
A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00642733 2016-08-24
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Hoffmann-La Roche
Phase 4 Terminated
NCT00674973 2016-06-17
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00461708 2015-10-15
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival
Hoffmann-La Roche
Phase 2 Completed
NCT00925769 2015-08-07
ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT00652366 2015-02-11
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00709826 2012-11-07
APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer
Tragara Pharmaceuticals, Inc.
Phase 2 Completed
NCT00536770 2007-11-06
A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer
Novacea
Phase 2 Suspended